Moderna Inc and Pfizer Inc launched two 30,000-subject trials of coronavirus vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Monday. The trials, both announced on Monday, are the first late-stage studies supported by the Trump administration’s effort to speed development of measures against the novel coronavirus, adding to hope that an effective vaccine will help end the pandemic. As the national capital recorded 613 fresh coronavirus cases on Monday, the lowest in the last two months, and recovery rate improved to 88 per cent, Chief Minister Arvind Kejriwal said while other cities are re-imposing lockdown, there was no such need in Delhi.